Table 2 BRAF and KRAS mutations and TP53 immunohistochemistry in colorectal carcinoma with signet ring cell and mucinous components and nonmucinous adenocarcinoma
Type of colorectal carcinoma | BRAF mutants (%) | KRAS mutants (%) | TP53 positive (%) |
|---|---|---|---|
Carcinoma with signet ring cell component (the signet group) | |||
≤19% | 7/21 (33%)d1 | 9/27 (33%) | 4/12 (33%) |
20–49% | 0/2 (0%) | 1/3 (33%) | 4/6 (67%) |
≤49% | 7/23 (30%)d2 | 10/30 (33%) | 8/18 (44%) |
≥50% | 2/9 (22%) | 0/8 (0%) | 3/4 (75%) |
Any | 9/32 (28%)d3 | 10/38 (26%) | 11/22 (50%) |
Carcinoma with mucinous component (the mucinous group) | |||
≤19% | 9/61 (15%) | 32/66 (48%)e3 | 22/54 (41%)a2 |
20–49% | 10/41 (24%)d4 | 17/39 (44%)a1 | 11/27 (41%) |
≤49% | 19/102 (19%)b1 | 49/105 (47%)d5 | 33/81 (41%)b2 |
≥50% | 14/51 (27%)e1 | 15/49 (31%) | 13/42 (31%)d7 |
Any | 33/153 (22%)e2 | 64/154 (42%)d6 | 46/123 (37%)d8 |
Nonmucinous adenocarcinoma | 30/348 (8.6%)d1,d2,d3,d4,b1,e1,e2 | 102/376 (27%)e3,a1,d5,d6 | 181/322 (56%)a2,b2,d7,d8 |
